Fangsheng Pharmaceutical: Huzhong Tongluo Tablets II Phase Clinical Trial Summary Report

Fangsheng Pharmaceutical announced that the company's research and development of traditional Chinese medicine innovative drug Zhielong Tongluo Tablets has obtained a Phase II clinical research report. Clinical trial results show that Zhielong Tongluo Tablets have significant effects in the recovery period of cerebral infarction treatment, with comparable efficacy in high-dose and low-dose groups, and good safety. Currently, Zhielong Tongluo Tablets are the company's exclusive product, and no other company has obtained the production approval for this product. In terms of market, sales of traditional Chinese medicines for treating cerebral infarction such as Naoxintong Capsules and Tongxinluo Capsules in 2024 were 2.927 billion yuan and 2.273 billion yuan respectively.